Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Download PDF

    Clinical Trial Results:
    Abrocitinib Expanded Access Protocol for the Treatment of Adolescents and Adults With Moderate to Severe Atopic Dermatitis

    Summary
    EudraCT number
    2020-003610-12
    Trial protocol
    NL   AT   ES   GR   BE  
    Global end of trial date
    02 Sep 2024

    Results information
    Results version number
    v1(current)
    This version publication date
    09 Mar 2025
    First version publication date
    09 Mar 2025
    Other versions

    Trial information

    Close Top of page
    Trial identification
    Sponsor protocol code
    B7451064
    Additional study identifiers
    ISRCTN number
    -
    US NCT number
    NCT04564755
    WHO universal trial number (UTN)
    -
    Sponsors
    Sponsor organisation name
    Pfizer Inc
    Sponsor organisation address
    66 Hudson Boulevard East, New York, United States, NY 10017
    Public contact
    Pfizer ClinicalTrials.gov Call Center, Pfizer Inc, 001 8007181021, ClinicalTrials.gov_Inquiries@pfizer.com
    Scientific contact
    Pfizer ClinicalTrials.gov Call Center, Pfizer Inc, 001 8007181021, ClinicalTrials.gov_Inquiries@pfizer.com
    Paediatric regulatory details
    Is trial part of an agreed paediatric investigation plan (PIP)
    No
    Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?
    Yes
    Results analysis stage
    Analysis stage
    Final
    Date of interim/final analysis
    25 Sep 2024
    Is this the analysis of the primary completion data?
    Yes
    Primary completion date
    02 Aug 2024
    Global end of trial reached?
    Yes
    Global end of trial date
    02 Sep 2024
    Was the trial ended prematurely?
    Yes
    General information about the trial
    Main objective of the trial
    To provide access to Abrocitinib to adolescent and adult participants with or without background topical therapy who had inadequate treatment options due to inadequate response or intolerance to available approved medicated topical and systemic therapies, underlying conditions that preclude use of available approved medicated topical and systemic therapies, or lack of availability or access to approved medicated topical and systemic therapies and need Abrocitinib as a possible treatment regimen for moderate to severe atopic dermatitis (AD).
    Protection of trial subjects
    The study was in compliance with the ethical principles derived from the Declaration of Helsinki and in compliance with all International Council for Harmonisation (ICH) Good Clinical Practice (GCP) Guidelines. All the local regulatory requirements pertinent to safety of trials participants were followed.
    Background therapy
    -
    Evidence for comparator
    -
    Actual start date of recruitment
    18 Nov 2020
    Long term follow-up planned
    No
    Independent data monitoring committee (IDMC) involvement?
    Yes
    Population of trial subjects
    Number of subjects enrolled per country
    Country: Number of subjects enrolled
    Australia: 19
    Country: Number of subjects enrolled
    Austria: 10
    Country: Number of subjects enrolled
    Belgium: 16
    Country: Number of subjects enrolled
    Canada: 25
    Country: Number of subjects enrolled
    Netherlands: 1
    Country: Number of subjects enrolled
    Russian Federation: 1
    Country: Number of subjects enrolled
    Spain: 21
    Country: Number of subjects enrolled
    Switzerland: 12
    Country: Number of subjects enrolled
    Taiwan: 16
    Country: Number of subjects enrolled
    United States: 191
    Worldwide total number of subjects
    312
    EEA total number of subjects
    48
    Number of subjects enrolled per age group
    In utero
    0
    Preterm newborn - gestational age < 37 wk
    0
    Newborns (0-27 days)
    0
    Infants and toddlers (28 days-23 months)
    0
    Children (2-11 years)
    0
    Adolescents (12-17 years)
    33
    Adults (18-64 years)
    245
    From 65 to 84 years
    34
    85 years and over
    0

    Subject disposition

    Close Top of page
    Recruitment
    Recruitment details
    -

    Pre-assignment
    Screening details
    A total of 316 participants were enrolled at 44 centers in 10 countries/regions.

    Period 1
    Period 1 title
    Overall Period
    Is this the baseline period?
    Yes
    Allocation method
    Not applicable
    Blinding used
    Not blinded

    Arms
    Arm title
    Abrocitinib
    Arm description
    Participants received abrocitinib 100milligrams (mg) or 200 mg tablet orally once a day (QD)
    Arm type
    Experimental

    Investigational medicinal product name
    Abrocitinib
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Tablet
    Routes of administration
    Oral use
    Dosage and administration details
    Participants received Abrocitinib 200 mg tablet orally every day (QD)

    Investigational medicinal product name
    Abrocitinib
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Tablet
    Routes of administration
    Oral use
    Dosage and administration details
    Participants received Abrocitinib 100 mg tablet orally every day (QD)

    Number of subjects in period 1
    Abrocitinib
    Started
    312
    Completed
    184
    Not completed
    128
         Adverse event, serious fatal
    2
         Physician decision
    1
         Consent withdrawn by subject
    35
         Other, unspecified
    1
         Pregnancy
    1
         Medication error without associated adverse event
    1
         Study terminated by sponsor
    17
         Other, Adverse event
    29
         Lost to follow-up
    23
         Withdrawal by parent/guardian
    1
         Lack of efficacy
    12
         Protocol deviation
    5

    Baseline characteristics

    Close Top of page
    Baseline characteristics reporting groups
    Reporting group title
    Overall Period
    Reporting group description
    Participants received abrocitinib 100 mg or 200 mg tablet orally once a day (QD)

    Reporting group values
    Overall Period Total
    Number of subjects
    312 312
    Age categorical
    Units: Subjects
        In Utero
    0 0
        Preterm newborn infants (gestional age < 37 wks)
    0 0
        Newborns (0-27 days)
    0 0
        Infants and toddlers (28 days - 23 months)
    0 0
        Children (2 - 11 years)
    0 0
        12 - 17 years
    33 33
        Adults (18 - 64 years)
    245 245
        From 65 - 84 years
    34 34
        85 years and over
    0 0
    Age continuous
    Units: years
        arithmetic mean (standard deviation)
    38.0 ( 18.47 ) -
    Gender categorical
    Units: Subjects
        Male
    167 167
        Female
    145 145
    Race
    Units: Subjects
        White
    217 217
        Black or African American
    43 43
        Asian
    44 44
        Native Hawaiian or Other Pacific Islander
    3 3
        Multiracial
    2 2
        Not Reported
    3 3
    Ethnicity
    Units: Subjects
        Hispanic or Latino
    43 43
        Not Hispanic or Latino
    261 261
        Not Reported
    8 8

    End points

    Close Top of page
    End points reporting groups
    Reporting group title
    Abrocitinib
    Reporting group description
    Participants received abrocitinib 100milligrams (mg) or 200 mg tablet orally once a day (QD)

    Primary: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)

    Close Top of page
    End point title
    Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) [1]
    End point description
    An AE was any untoward medical occurrence in a participant or clinical study participant, temporally associated with use of study intervention, whether or not considered related to study intervention. An event was considered a TEAE if event started during the effective duration of treatment with investigational product. All events that started on or after first dosing day, but before or on the last dosing day plus lag time (28 days) were considered as TEAEs. SAE was an AE resulting in any of below outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalisation; life-threatening experience persistent or significant disability/incapacity; congenital anomaly; was a suspected transmission via a Pfizer product of an infectious agent, pathogenic or non-pathogenic or other situations where medical or scientific judgement should be exercised by investigator. AEs:SAEs and all non-SAEs. Safety set was analysed.
    End point type
    Primary
    End point timeframe
    From the first dose of study treatment up to 4 weeks post end of study treatment (maximum exposure up to 155 weeks)
    Notes
    [1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: No statistical analysis have been defined.
    End point values
    Abrocitinib
    Number of subjects analysed
    312
    Units: Participants
        Participants with TEAEs
    244
        Participants with SAEs
    17
    No statistical analyses for this end point

    Primary: Number of Participants With Treatment-Emergent Serious Infections

    Close Top of page
    End point title
    Number of Participants With Treatment-Emergent Serious Infections [2]
    End point description
    Serious infections, defined as any infection (viral, bacterial, and fungal) requiring hospitalisation or parenteral antimicrobials. Safety analysis set included all participants who received at least 1 dose of study intervention.
    End point type
    Primary
    End point timeframe
    From the first dose of study treatment up to 4 weeks post end of study treatment (maximum exposure up to 155 weeks)
    Notes
    [2] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: No statistical analysis have been defined.
    End point values
    Abrocitinib
    Number of subjects analysed
    312
    Units: Participants
    4
    No statistical analyses for this end point

    Primary: Number of Participants who Discontinued Study or Study Drug due to AEs and SAEs Respectively

    Close Top of page
    End point title
    Number of Participants who Discontinued Study or Study Drug due to AEs and SAEs Respectively [3]
    End point description
    An AE is any untoward medical occurrence in a participant who received study treatment without regard to possibility of causal relationship. SAE is an AE resulting in any of the following outcomes or deemed significant for any other reason: death, initial or prolonged inpatient hospitalisation, life-threatening experience (immediate risk of dying), persistent or significant disability or incapacity, congenital anomaly. Number of participants who discontinued study and study drug due to AEs and SAEs were reported in this outcome measure. Safety analysis set included all participants who received at least 1 dose of study intervention.
    End point type
    Primary
    End point timeframe
    From the first dose of study treatment up to 4 weeks post end of study treatment (maximum exposure up to155 weeks)
    Notes
    [3] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: No statistical analysis have been defined.
    End point values
    Abrocitinib
    Number of subjects analysed
    312
    Units: Participants
        Due toAE
    8
        Due to AE and continue Study
    25
        Due to SAE
    3
        Due to SAE and continue Study
    7
    No statistical analyses for this end point

    Adverse events

    Close Top of page
    Adverse events information
    Timeframe for reporting adverse events
    From the time of signing the informed consent up to 4 weeks post end of study treatment (maximum exposure up to 155 weeks)
    Adverse event reporting additional description
    Same event may appear as both AE and SAE but are distinct events. An event may be categorised as serious in 1 participant and non-serious in another, or a participant may have experienced both SAE and non-SAE.
    Assessment type
    Non-systematic
    Dictionary used for adverse event reporting
    Dictionary name
    MedDRA
    Dictionary version
    v27.0
    Reporting groups
    Reporting group title
    Abrocitinib
    Reporting group description
    Participants received abrocitinib 100 mg or 200 mg tablet orally once a day (QD)

    Serious adverse events
    Abrocitinib
    Total subjects affected by serious adverse events
         subjects affected / exposed
    17 / 312 (5.45%)
         number of deaths (all causes)
    2
         number of deaths resulting from adverse events
    2
    Neoplasms benign, malignant and unspecified (incl cysts and polyps)
    Adenocarcinoma of colon
         subjects affected / exposed
    1 / 312 (0.32%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Immune system disorders
    Drug hypersensitivity
         subjects affected / exposed
    1 / 312 (0.32%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Respiratory, thoracic and mediastinal disorders
    Pulmonary oedema
         subjects affected / exposed
    1 / 312 (0.32%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Pulmonary embolism
         subjects affected / exposed
    1 / 312 (0.32%)
         occurrences causally related to treatment / all
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    Dyspnoea
         subjects affected / exposed
    1 / 312 (0.32%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Acute respiratory distress syndrome
         subjects affected / exposed
    1 / 312 (0.32%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Psychiatric disorders
    Generalised anxiety disorder
         subjects affected / exposed
    1 / 312 (0.32%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Injury, poisoning and procedural complications
    Ligament rupture
         subjects affected / exposed
    1 / 312 (0.32%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Tendon injury
         subjects affected / exposed
    1 / 312 (0.32%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Tendon rupture
         subjects affected / exposed
    1 / 312 (0.32%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Cardiac disorders
    Hypertensive heart disease
         subjects affected / exposed
    1 / 312 (0.32%)
         occurrences causally related to treatment / all
    1 / 1
         deaths causally related to treatment / all
    1 / 1
    Nervous system disorders
    Syncope
         subjects affected / exposed
    1 / 312 (0.32%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Cerebral venous thrombosis
         subjects affected / exposed
    1 / 312 (0.32%)
         occurrences causally related to treatment / all
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    Blood and lymphatic system disorders
    Thrombocytopenia
         subjects affected / exposed
    1 / 312 (0.32%)
         occurrences causally related to treatment / all
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    Gastrointestinal disorders
    Gastroduodenal ulcer
         subjects affected / exposed
    1 / 312 (0.32%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Duodenal ulcer
         subjects affected / exposed
    1 / 312 (0.32%)
         occurrences causally related to treatment / all
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    Hepatobiliary disorders
    Hepatic function abnormal
         subjects affected / exposed
    1 / 312 (0.32%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Renal and urinary disorders
    Calculus urinary
         subjects affected / exposed
    1 / 312 (0.32%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Infections and infestations
    Skin bacterial infection
         subjects affected / exposed
    1 / 312 (0.32%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Urosepsis
         subjects affected / exposed
    1 / 312 (0.32%)
         occurrences causally related to treatment / all
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    Renal abscess
         subjects affected / exposed
    1 / 312 (0.32%)
         occurrences causally related to treatment / all
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    Ophthalmic herpes zoster
         subjects affected / exposed
    1 / 312 (0.32%)
         occurrences causally related to treatment / all
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    COVID-19 pneumonia
         subjects affected / exposed
    1 / 312 (0.32%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 1
    COVID-19
         subjects affected / exposed
    1 / 312 (0.32%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Metabolism and nutrition disorders
    Type 1 diabetes mellitus
         subjects affected / exposed
    1 / 312 (0.32%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Frequency threshold for reporting non-serious adverse events: 5%
    Non-serious adverse events
    Abrocitinib
    Total subjects affected by non serious adverse events
         subjects affected / exposed
    162 / 312 (51.92%)
    Nervous system disorders
    Headache
         subjects affected / exposed
    27 / 312 (8.65%)
         occurrences all number
    33
    Gastrointestinal disorders
    Nausea
         subjects affected / exposed
    48 / 312 (15.38%)
         occurrences all number
    54
    Skin and subcutaneous tissue disorders
    Dermatitis atopic
         subjects affected / exposed
    41 / 312 (13.14%)
         occurrences all number
    51
    Acne
         subjects affected / exposed
    28 / 312 (8.97%)
         occurrences all number
    29
    Infections and infestations
    Upper respiratory tract infection
         subjects affected / exposed
    21 / 312 (6.73%)
         occurrences all number
    26
    COVID-19
         subjects affected / exposed
    51 / 312 (16.35%)
         occurrences all number
    54

    More information

    Close Top of page

    Substantial protocol amendments (globally)

    Were there any global substantial amendments to the protocol? Yes
    Date
    Amendment
    07 Dec 2020
    The main reason for the protocol amendment was to update Appendix 2 The Table of Protocol Required Safety Laboratory tests to reflect minimally required clinical chemistry and hematology parameters to be tested. Other changes included clarifications to the following: • Hepatitis B testing • Exclusion criterion 15 to reflect that participants who are vaccinated with live components within 6 weeks prior to the first dose of Abrocitinib or who are expected to be vaccinated with these vaccines during treatment or during the 6 weeks following discontinuation of Abrocitinib are not eligible for study participation. • Lifestyle Considerations text regarding vaccination with live components has been updated to align with exclusion criterion 15 text • Permitted use of corticosteroid inhalers and intranasal sprays and ophthalmic corticosteroid to reflect that use of a stable dose of these permitted medications is not required. • Concomitant treatment monitoring to specify that monitoring of both medications and non-drug treatments will occur. • Rater Qualifications has been clarified. • Addition of reference regarding blood sample volumes in children added to the Study Assessments and Procedures section

    Interruptions (globally)

    Were there any global interruptions to the trial? No

    Limitations and caveats

    Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.
    None reported
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 03 01:30:08 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA